Aletaha, D. et al. (2023) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases, 82(6), pp. 773-787. (doi: 10.1136/ard-2022-222784) (PMID:35953263)
Text
277636.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial. 629kB |
Abstract
Background: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. Methods: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. Results: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still’s disease, Castleman’s disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. Conclusions: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
Item Type: | Articles |
---|---|
Keywords: | Biological therapy, autoimmune diseases, rheumatoid arthritis. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | McInnes, Professor Iain and Sattar, Professor Naveed |
Authors: | Aletaha, D., Kerschbaumer, A., Kastrati, K., Dejaco, C., Dougados, M., McInnes, I. B., Sattar, N., Stamm, T. A., Takeuchi, T., Trauner, M., van der Heijde, D., Voshaar, M., Winthrop, K. L., Ravelli, A., Betteridge, N., Burmester, G.-R. R., Bijlsma, J. W.J., Bykerk, V., Caporali, R., Choy, E. H., Codreanu, C., Combe, B., Crow, M. K., de Wit, M., Emery, P., Fleischmann, R. M., Gabay, C., Hetland, M. L., Hyrich, K. L., Iagnocco, A., Isaacs, J. D., Kremer, J. M., Mariette, X., Merkel, P. A., Mysler, E. F., Nash, P., Nurmohamed, M. T., Pavelka, K., Poor, G., Rubbert-Roth, A., Schulze-Koops, H., Strangfeld, A., Tanaka, Y., and Smolen, J. S. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Research Centre: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology |
Journal Name: | Annals of the Rheumatic Diseases |
Publisher: | BMJ Publishing Group |
ISSN: | 0003-4967 |
ISSN (Online): | 1468-2060 |
Published Online: | 11 August 2022 |
Copyright Holders: | Copyright © 2022 The Authors |
First Published: | First published in Annals of the Rheumatic Diseases 82(6):773-787 |
Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record